Reset filter
Palabras clave
D016430 ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
    1. 7.1. Anestesiología
    1. 7.2. Dermatología
    1. 7.3. ENT
    1. 7.4. Geriatría
    1. 7.5. Ginecología / Obstetricia
    1. 7.6. Medicina Interna
      1. Hematología
      1. Enfermedades infecciosas
      1. Cardiología / Angiología
      1. Neumología
      1. Gastroenterología
      1. Nefrología
      1. Endocrinología / Enfermedades metabólicas
      1. Reumatología
    1. 7.7. Neurología
    1. 7.8. Oftalmología
    1. 7.9. Cuidados paliativos
    1. 7.10. Patología / Forense
    1. 7.11. Pediatría
    1. 7.12. Psiquiatría / Psicosomática
    1. 7.13. Radiología
    1. 7.14. Cirugía
      1. Cirugía General / Visceral
      1. Neurocirugía
      1. Cirugía plástica
      1. Cirugía Torácica
      1. Traumatología / Ortopedia
      1. Cirugía vascular
    1. 7.15. Urología
    1. 7.16. Odontología / OMS
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

125 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility Melanoma NCT00147550

- 19/10/16 - 1 formulario, 2 itemgroups, 16 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00147550

Eligibility Melanoma NCT02475213

- 8/5/19 - 1 formulario, 2 itemgroups, 17 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02475213

Eligibility Melanoma NCT02381314

- 7/5/19 - 1 formulario, 2 itemgroups, 13 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02381314

Eligibility NCT00522834 Melanoma - Eligibility

- 20/9/21 - 1 formulario, 2 itemgroups, 13 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00522834

Eligibility DRKS00003621 NCT00518895 Melanoma - Eligibility

- 20/9/21 - 1 formulario, 2 itemgroups, 16 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00518895

Eligibility NCT00395070 Metastatic Melanoma - Eligibility

- 15/4/14 - 1 formulario, 2 itemgroups, 11 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00395070

Basic Documentation, Medical History 1/2, Melanoma NCT00000000 - Basis Doku, Anamnese 1/2, Melanom NCT00000000

- 16/7/16 - 1 formulario, 4 itemgroups, 27 items, 2 idiomas
Itemgroups: Patient identification, Classification of Anamnesis, Consent, Anamnesis and risk factors Part A
Klinik und Poliklinik für Hautkrankheiten - Allgemeine Dermatologie und Venerologie - Direktor: Univ.-Prof. Dr. med. Th. A. Luger

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Rheumatic Diseases; Systemic Lupus Erythematosus or Cutaneous Lupus; Sjogren's Syndrome (Report Final and Annex Report 2 Final)

- 2/11/20 - 1 formulario, 25 itemgroups, 95 items, 1 idioma
Itemgroups: Administrative, Rheumatic Diseases, Rheumatic Diseases - Signs and Symptoms, Rheumatic diseases - Other signs and symptoms, Rheumatic diseases - Other signs and symptoms , Rheumatic diseases - Diagnostic Test Results, Rheumatic diseases - Other Diagnostic Test Results , Rheumatic diseases - Other Diagnostic Test Results , Rheumatic diseases - Other diagnostic Procedure, Systemic Lupus Erythematosus or Cutaneous Lupus, Systemic Lupus Erythematosus or Cutaneous Lupus - Signs and symptoms (supporting the final diagnosis), Systemic Lupus Erythematosus or Cutaneous Lupus - Other Signs and symptoms, Systemic Lupus Erythematosus or Cutaneous Lupus - Other Signs and symptoms , Systemic Lupus Erythematosus or Cutaneous Lupus - Diagnostic Test Results, Systemic Lupus Erythematosus or Cutaneous Lupus - Other Diagnostic Test Results , Systemic Lupus Erythematosus or Cutaneous Lupus - Other Diagnostic Test Results , Systemic Lupus Erythematosus or Cutaneous Lupus - Other diagnostic Procedure , Sjogren's Syndrome, Sjogren's Syndrome - Signs and symptoms (supporting the final diagnosis), Sjogren's Syndrome - Other Signs and symptoms , Sjogren's Syndrome - Other Signs and symptoms , Sjogren's Syndrome - Diagnostic Test Results , Sjogren's Syndrome - Other Diagnostic Test Results , Sjogren's Syndrome - Other Diagnostic Test Results , Sjogren's Syndrome - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Eligibility NCT00844064 Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms - Eligibility

- 20/9/21 - 1 formulario, 2 itemgroups, 33 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00844064

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Screening - Primary Tumor Characteristics; Regional Lymph Node Status; Tumor Sample (Annex Report 2 Final Annex Report 2 Final)

- 20/9/21 - 1 formulario, 4 itemgroups, 27 items, 1 idioma
Itemgroups: Administrative, Primary Tumor Characteristics, Regional Lymph Node Status, Tumor Sample
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Eligibility Check (Annex Report 2 Final)

- 17/9/21 - 1 formulario, 4 itemgroups, 29 items, 1 idioma
Itemgroups: Administrative, Eligibility Check, Inclusion Criteria, Exclusion Criteria
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Eligibility Check

- 17/9/21 - 1 formulario, 4 itemgroups, 29 items, 1 idioma
Itemgroups: Administrative, Eligibility Check, Inclusion Criteria, Exclusion Criteria
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial